Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Depressive Symptoms in Elderly with Visual Impairment
NCT03473431Completed
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ketamine in major depressive disorder (MDD), sponsored by Instituto Mexicano del Seguro Social. Primary endpoint: Geriatric Depression Scale at 24 hours. Started Apr 2018; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03473431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473431.